Show simple item record

dc.contributor.authorOffice of Marketing and Communications. Media Relations
dc.date.accessioned2018-11-06T13:24:12Z
dc.date.available2018-11-06T13:24:12Z
dc.date.issued2018-10-04
dc.identifier.urihttps://hdl.handle.net/1813/60091
dc.description.abstractThis news item from the Cornell Chronicle is about: Crohn’s disease (CD), a chronic inflammatory condition of the intestinal tract, has emerged as a global disease, with rates steadily increasing over the last 50 years. Experts have long suspected that CD likely represents a collection of related but slightly different disorders, but until now it has not been possible to predict accurately which subtype of CD a patient is likely to develop. In a study published Oct. 4 in the journal JCI Insight, Cornell and University of North Carolina researchers report they have pinpointed a single molecule – microRNA-31 (miR-31) – the levels of which predict whether a patient has subtype 1 or subtype 2 of the disease.
dc.language.isoen_US
dc.publisherCornell University, College of Veterinary Medicine
dc.subjectCornell University. College of Veterinary Medicine -- Periodicals.
dc.subjectSethupathy, Praveen
dc.subjectRamanujan, Krishna
dc.subjectCornell Chronicle
dc.title2018 CVM News: Marker may help target treatments for Crohn’s patients
dc.typearticle


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Statistics